Access Pharmaceuticals, Inc. (ACCP.OB) Completes ProLindac Monotherapy Trial and Initiates Combination Study
Access Pharmaceuticals, Inc. announced this morning that it has completed enrollment and evaluation of the last additional group of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens. The additional group of 8 patients received the ProLindac batch made by an improved scalable process, which will be used on a larger scale for future clinical and commercial supplies. According to the press release, none of the patients experienced any acute significant adverse events. In addition, treatment had the same beneficial pharmacodynamic effect seen…